Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$1.17
+0.9%
$1.56
$1.09
$3.78
$255.89M0.63.30 million shs3.80 million shs
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$1.19
+5.3%
$1.24
$0.92
$22.50
$71.13M0.61326,347 shs142,531 shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$7.88
+11.8%
$11.52
$6.64
$30.60
$68.81M2.89147,385 shs99,891 shs
Varex Imaging Co. stock logo
VREX
Varex Imaging
$7.52
+9.3%
$9.76
$6.76
$16.93
$309.82M0.62571,742 shs932,700 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
+0.86%-27.78%-19.31%-16.43%-57.61%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
+4.39%-7.75%-0.83%-7.75%-87.26%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+11.77%-14.63%-33.28%-50.69%-61.37%
Varex Imaging Co. stock logo
VREX
Varex Imaging
+9.30%-11.01%-4.08%-44.30%-51.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
3.1991 of 5 stars
3.53.00.00.02.64.20.6
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
4.4472 of 5 stars
3.04.00.04.62.03.31.3
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.2414 of 5 stars
2.92.00.04.61.81.70.0
Varex Imaging Co. stock logo
VREX
Varex Imaging
4.5593 of 5 stars
3.54.00.04.02.90.81.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
2.90
Moderate Buy$9.29693.92% Upside
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
1.90
Reduce$5.50362.18% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.80
Reduce$73.67834.86% Upside
Varex Imaging Co. stock logo
VREX
Varex Imaging
3.00
Buy$22.50199.20% Upside

Current Analyst Ratings Breakdown

Latest VREX, ALLO, MCRB, and IGMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$1.25 ➝ $6.00
3/20/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
3/19/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$9.00 ➝ $8.00
3/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
3/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/14/2025
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$5.00
3/14/2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$20.00 ➝ $15.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
$22K11,631.13N/AN/A$3.04 per share0.38
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
$2.68M26.55N/AN/A$3.46 per share0.34
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.33M0.54N/AN/A($0.35) per share-22.51
Varex Imaging Co. stock logo
VREX
Varex Imaging
$827.50M0.37$0.80 per share9.35$13.45 per share0.56
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$327.27M-$1.33N/AN/AN/AN/A-52.13%-41.29%N/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$246.42M-$3.24N/AN/AN/A-7,534.03%-155.42%-61.04%5/14/2025 (Estimated)
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$113.72M-$4.60N/AN/AN/AN/AN/A-55.08%N/A
Varex Imaging Co. stock logo
VREX
Varex Imaging
-$47.70M-$1.03N/A13.19N/A-5.79%4.00%1.81%N/A

Latest VREX, ALLO, MCRB, and IGMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.41N/AN/AN/A$4.25 millionN/A
5/8/2025Q2 2025
Varex Imaging Co. stock logo
VREX
Varex Imaging
$0.14$0.26+$0.12$0.17$206.76 million$212.90 million
5/7/2025Q1 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$0.67-$2.24-$1.57$3.75$10.00 millionN/A
3/13/2025Q4 2024
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A
3/6/2025Q4 2024
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/AN/AN/AN/AN/A
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
Varex Imaging Co. stock logo
VREX
Varex Imaging
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
N/A
9.35
9.35
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
N/A
5.22
5.22
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.12
1.12
Varex Imaging Co. stock logo
VREX
Varex Imaging
1.02
4.36
2.50

Institutional Ownership

CompanyInstitutional Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
83.63%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
42.79%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%
Varex Imaging Co. stock logo
VREX
Varex Imaging
N/A

Insider Ownership

CompanyInsider Ownership
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
24.30%
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
57.00%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
Varex Imaging Co. stock logo
VREX
Varex Imaging
4.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
310218.71 million158.72 millionOptionable
IGM Biosciences, Inc. stock logo
IGMS
IGM Biosciences
19059.78 million25.57 millionOptionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.73 million162.03 millionOptionable
Varex Imaging Co. stock logo
VREX
Varex Imaging
2,30041.20 million39.43 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Allogene Therapeutics stock logo

Allogene Therapeutics NASDAQ:ALLO

$1.17 +0.01 (+0.86%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.21 +0.04 (+3.50%)
As of 04:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

IGM Biosciences stock logo

IGM Biosciences NASDAQ:IGMS

$1.19 +0.06 (+5.31%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$1.19 0.00 (-0.34%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$7.88 +0.83 (+11.77%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$7.55 -0.33 (-4.18%)
As of 04:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Varex Imaging stock logo

Varex Imaging NASDAQ:VREX

$7.52 +0.64 (+9.30%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$7.44 -0.09 (-1.13%)
As of 04:10 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. The company sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. It has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was incorporated in 2016 and is headquartered in Salt Lake City, Utah.